News from pivotal therapeutics inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 04, 2015, 14:25 ET

First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100

WOODBRIDGE, ON, June 4, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a...

Jun 01, 2015, 21:19 ET

Pivotal Therapeutics Announces First Quarter Financial Results

WOODBRIDGE, ON, June 1, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on...

May 11, 2015, 15:17 ET

Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel

WOODBRIDGE, May 11, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (CSE:PVO; OTCQX:PVTTF), ("Pivotal" or the "Company"), a specialty...

Apr 30, 2015, 21:20 ET

Pivotal Therapeutics Announces 2014 Financial Results

WOODBRIDGE, ON, April 30, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus...

Apr 27, 2015, 12:48 ET
Apr 15, 2015, 09:10 ET

Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial™ line of products in Korea

WOODBRIDGE, ON, April 15, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Apr 02, 2015, 06:54 ET

Pivotal recibe asignación de patente en Estados Unidos para VASCAZEN® y diagnóstico de ácido graso Omega-3

- Pivotal recibe notificación de asignación de patente en Estados Unidos relacionada con un kit para el tratamiento dietético de...

Apr 01, 2015, 15:44 ET

Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN® and an Omega-3 Fatty Acid Diagnostic Assay

WOODBRIDGE, ON, April 1, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Mar 26, 2015, 17:13 ET

Pivotal Therapeutics announces payment of interest on outstanding convertible notes

WOODBRIDGE, ON, March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Feb 10, 2015, 12:28 ET

Pivotal announces the issuance of two patents both related to the combination of VASCAZEN® with key Cholesterol Lowering Agents (Statins) and Cholesterol Absorption Inhibitors

WOODBRIDGE, ON, Feb. 10, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Jan 27, 2015, 13:23 ET

Pivotal Therapeutics Receives Final Approval for Phase IIa Clinical Trial With PVT-100

WOODBRIDGE, ON, Jan. 27, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Jan 22, 2015, 15:38 ET

Pivotal Therapeutics: Year in Review and CEO Update

WOODBRIDGE, ON, Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Jan 05, 2015, 17:10 ET

Pivotal Therapeutics announces payment of interest on outstanding convertible notes

WOODBRIDGE, ON, Jan. 5, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Dec 17, 2014, 07:38 ET

Permiso para la evaluación clínica del protocolo del ensayo VASCAZEN® POMEGA Phase IIa por medio de la FDA de Francia

Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" o la "compañía"), una compañía farmacéutica especializada...

Dec 17, 2014, 07:30 ET

VASCAZEN® POMEGA Phase IIa trial protocol cleared clinical evaluation by French FDA

WOODBRIDGE, ON, Dec. 17, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Nov 28, 2014, 17:22 ET

Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results

WOODBRIDGE, ON, Nov. 28, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Nov 14, 2014, 15:15 ET

Pivotal Therapeutics Announces Senior Management Change

WOODBRIDGE, ON, Nov. 14, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Oct 09, 2014, 11:40 ET

Pivotal recibe la notificación de patente de VASCAZEN® y el inhibidor de absorción de colesterol

- Pivotal recibe la notificación de permiso de patente de Estados Unidos relacionada con la combinación de VASCAZEN® y el inhibidor...

Oct 08, 2014, 12:44 ET

Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor

WOODBRIDGE, ON, Oct. 8, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...